Gland Pharma Limited (GLAND) - Net Assets

Latest as of March 2026: Rs103.58 Billion INR ≈ $1.12 Billion USD

Based on the latest financial reports, Gland Pharma Limited (GLAND) has net assets worth Rs103.58 Billion INR (≈ $1.12 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs125.11 Billion ≈ $1.35 Billion USD) and total liabilities (Rs21.53 Billion ≈ $232.83 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GLAND tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs103.58 Billion
% of Total Assets	82.79%
Annual Growth Rate	19.47%
5-Year Change	44.71%
10-Year Change	N/A
Growth Volatility	15.96

Gland Pharma Limited - Net Assets Trend (2017–2026)

This chart illustrates how Gland Pharma Limited's net assets have evolved over time, based on quarterly financial data. See GLAND defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Gland Pharma Limited (2017–2026)

The table below shows the annual net assets of Gland Pharma Limited from 2017 to 2026. For live valuation and market cap data, see GLAND market cap overview.

Year	Net Assets	Change
2026-03-31	Rs103.58 Billion ≈ $1.12 Billion	+13.19%
2025-03-31	Rs91.51 Billion ≈ $989.62 Million	+4.89%
2024-03-31	Rs87.24 Billion ≈ $943.45 Million	+9.61%
2023-03-31	Rs79.59 Billion ≈ $860.71 Million	+11.19%
2022-03-31	Rs71.58 Billion ≈ $774.07 Million	+21.25%
2021-03-31	Rs59.03 Billion ≈ $638.41 Million	+61.90%
2020-03-31	Rs36.46 Billion ≈ $394.33 Million	+27.40%
2019-03-31	Rs28.62 Billion ≈ $309.51 Million	+18.74%
2018-03-31	Rs24.10 Billion ≈ $260.67 Million	+15.34%
2017-03-31	Rs20.90 Billion ≈ $226.01 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Gland Pharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2026)

Component	Amount	Percentage
Common Stock	Rs164.76 Million	0.16%
Other Components	Rs103.41 Billion	99.84%
Total Equity	Rs103.58 Billion	100.00%

Gland Pharma Limited Competitors by Market Cap

The table below lists competitors of Gland Pharma Limited ranked by their market capitalization.

Company	Market Cap
MAZDA MOTOR UNSP.ADR/2 F:MZA0	$3.92 Billion
DKSH Holding AG SW:DKSH	$3.92 Billion
Vallourec PA:VK	$3.92 Billion
Orla Mining Ltd TO:OLA	$3.93 Billion
Shanghai Xinmei Real Estate Co Ltd Class A SHG:600732	$3.92 Billion
Titan Cement International SA BR:TITC	$3.92 Billion
Sinomach Heavy Equipment Group Co Ltd SHG:601399	$3.92 Billion
Indivior PLC Ordinary Shares NASDAQ:INDV	$3.91 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Gland Pharma Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2025 to 2026, total equity changed from 91,507,410,000 to 103,579,500,000, a change of 12,072,090,000 (13.2%).
Net income of 10,273,160,000 contributed positively to equity growth.
Dividend payments of 2,965,510,000 reduced retained earnings.
Other comprehensive income decreased equity by 412,280,000.
Other factors increased equity by 5,176,720,000.

Equity Change Factors (2025 to 2026)

Factor	Impact	Contribution
Net Income	Rs10.27 Billion	+9.92%
Dividends Paid	Rs2.97 Billion	-2.86%
Other Comprehensive Income	Rs-412.28 Million	-0.4%
Other Changes	Rs5.18 Billion	+5.0%
Total Change	Rs-	13.19%

Book Value vs Market Value Analysis

This analysis compares Gland Pharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 3.50x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 16.29x to 3.50x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-03-31	Rs134.87	Rs2197.60	x
2018-03-31	Rs155.56	Rs2197.60	x
2019-03-31	Rs184.71	Rs2197.60	x
2020-03-31	Rs235.32	Rs2197.60	x
2021-03-31	Rs372.97	Rs2197.60	x
2022-03-31	Rs435.01	Rs2197.60	x
2023-03-31	Rs483.28	Rs2197.60	x
2024-03-31	Rs529.57	Rs2197.60	x
2025-03-31	Rs555.45	Rs2197.60	x
2026-03-31	Rs627.94	Rs2197.60	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Gland Pharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 9.92%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 15.98%
• Asset Turnover: 0.51x
• Equity Multiplier: 1.21x
Recent ROE (9.92%) is below the historical average (14.01%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2017	19.80%	27.97%	0.60x	1.18x	Rs2.05 Billion
2018	13.32%	19.82%	0.55x	1.22x	Rs800.15 Million
2019	15.79%	22.10%	0.58x	1.23x	Rs1.66 Billion
2020	21.20%	29.35%	0.64x	1.12x	Rs4.08 Billion
2021	16.89%	28.79%	0.53x	1.10x	Rs4.07 Billion
2022	16.93%	27.53%	0.56x	1.09x	Rs4.96 Billion
2023	9.81%	21.55%	0.41x	1.10x	Rs-148.29 Million
2024	8.85%	13.64%	0.53x	1.22x	Rs-999.24 Million
2025	7.63%	12.44%	0.50x	1.23x	Rs-2.17 Billion
2026	9.92%	15.98%	0.51x	1.21x	Rs-84.79 Million

Industry Comparison

This section compares Gland Pharma Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $21,181,792,391
Average return on equity (ROE) among peers: 16.24%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Gland Pharma Limited (GLAND)	Rs103.58 Billion	19.80%	0.21x	$3.92 Billion
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$1.14 Billion	5.77%	1.16x	$24.73 Million
Aarti Drugs Limited (AARTIDRUGS)	$13.69 Billion	12.28%	0.88x	$362.94 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$2.27 Million	-2.03%	0.10x	$635.44 Million
Abbott India Limited (ABBOTINDIA)	$28.20 Billion	28.32%	0.50x	$5.96 Billion
Ajanta Pharma Limited (AJANTPHARM)	$35.67 Billion	22.88%	0.30x	$4.16 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$30.64 Billion	11.04%	0.34x	$979.45 Million
Alkem Laboratories Limited (ALKEM)	$63.09 Billion	17.86%	0.58x	$6.91 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$234.13 Million	25.26%	0.77x	$166.82 Million
Alembic Pharmaceuticals Limited (APLLTD)	$31.90 Billion	25.98%	0.88x	$1.59 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$7.25 Billion	14.99%	1.57x	$8.85 Billion

About Gland Pharma Limited

NSE:GLAND India Drug Manufacturers - Specialty & Generic

Market Cap

$3.92 Billion

Rs362.52 Billion INR

Market Cap Rank

#4242 Global

#179 in India

Share Price

Rs2197.60

Change (1 day)

+0.87%

52-Week Range

Rs1596.80 - Rs2334.00

All Time High

Rs4272.42